{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:28Z","timestamp":1792004368218,"version":"4.4.0"},"reference-count":54,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>New Delhi metallo-\u03b2-lactamase (NDM)-producing Enterobacterales represent a major therapeutic challenge due to their resistance to nearly all \u03b2-lactams and frequent co-resistance to other antibiotic classes, leaving clinicians with few effective options. These challenges are amplified in orthopedic infections with hardware involvement, where biofilm formation and the need for prolonged antimicrobial therapy limit success. We describe a 55-year-old female with a history of right type 3 open pilon fracture complicated by hardware failure and revision, who presented with septic tibial nonunion and chronic drainage. During this admission, she underwent irrigation and debridement with hardware removal and intramedullary nail placement. Cultures grew Enterobacter cloacae complex resistant to meropenem, ceftazidime\u2013avibactam, meropenem\u2013vaborbactam, and cefiderocol, as well as Candida parapsilosis. Molecular testing confirmed NDM production, while reference testing showed susceptibility to aztreonam\u2013avibactam (ATM-AVI). The patient was treated with ATM-AVI plus micafungin, achieving clinical stability within three days. Due to outpatient administration barriers with ATM-AVI, the patient was transitioned to eravacycline and micafungin. At eight-week follow-up, the patient remained clinically improved without relapse or adverse effects. This case highlights ATM-AVI as a critical therapy for NDM-producing orthopedic infections involving hardware and supports eravacycline as a feasible step-down option in outpatient management.<\/jats:p>","DOI":"10.3390\/antibiotics14111109","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:11:16Z","timestamp":1762254676000},"page":"1109","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of Aztreonam\u2013Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae"],"prefix":"10.3390","volume":"14","author":[{"given":"Jacob M.","family":"Keck","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9540-2683","authenticated-orcid":false,"given":"Ryan K.","family":"Dare","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3595-2274","authenticated-orcid":false,"given":"Michael","family":"Saccente","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur S.","family":"Vyas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah N.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rankin, D.A., Stahl, A., Sabour, S., Khan, M.A., Armstrong, T., Huang, J.Y., Baggs, J., and Walters, M.S. (2025). Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019 to 2023. Ann. Intern. Med., Epub ahead of print.","DOI":"10.7326\/ANNALS-25-02404"},{"key":"ref_3","first-page":"672","article-title":"NDM-1 (New Delhi metallo beta lactamase-1) producing Gram-negative bacilli: Emergence & clinical implications","volume":"140","author":"Fomda","year":"2014","journal-title":"Indian. J. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/jac\/dkq520","article-title":"Does broad-spectrum \u03b2-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?","volume":"66","author":"Nordmann","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"dlae141","DOI":"10.1093\/jacamr\/dlae141","article-title":"Emergence of high-level aztreonam\u2013avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline","volume":"6","author":"Haidar","year":"2024","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s10096-024-04911-x","article-title":"Failure of ceftazidime\/avibactam experimental therapy in the treatment of Klebsiella pneumoniae ST11 co-producing NDM-1 and OXA-48 carbapenemases infection","volume":"43","author":"Nikbin","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s15010-025-02488-x","article-title":"Clinical outcomes of patients hospitalized in internal medicine wards adequately treated for bloodstream infections caused by NDM-producing Klebsiella pneumoniae. Results from a real-life retrospective multi-center study in an endemic area","volume":"53","author":"Meini","year":"2025","journal-title":"Infection"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jgar.2025.08.014","article-title":"Prevalence, Clinical Characteristics, and Mortality Impact of Metallo-\u03b2-Lactamase-Producing Enterobacter Cloacae Complex Infections: A Retrospective Cohort Study","volume":"45","author":"Lee","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.cmi.2025.06.015","article-title":"Challenges and strategies in the treatment of periprosthetic joint infection caused by multidrug-resistant Gram-negative bacteria: A narrative review","volume":"31","author":"Murillo","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100466","DOI":"10.1016\/j.jorep.2024.100466","article-title":"Antimicrobial resistance (AMR) in Orthopaedic surgeries: A Complex issue and global threat","volume":"4","author":"Lakhani","year":"2025","journal-title":"J. Orthop. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1451398","DOI":"10.3389\/fcimb.2024.1451398","article-title":"Rising challenges in periprosthetic joint infections: A focus on rare pathogens and their clinical implications","volume":"14","author":"Lyu","year":"2024","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5704\/MOJ.2207.005","article-title":"A Multi-Disciplinary Approach for the Management of Prosthetic Joint Infections: An Australian Perspective","volume":"16","author":"Sires","year":"2022","journal-title":"Malays. Orthop. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.21037\/aoj-2020-04","article-title":"The multidisciplinary approach to managing prosthetic joint infection: Could this lead to improved outcomes?","volume":"7","author":"Sandiford","year":"2020","journal-title":"Ann. Jt."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12891-025-08329-0","article-title":"Implementation of multidisciplinary team decisions on the management of complex bone and joint infections: An observational study","volume":"26","author":"Hanssen","year":"2025","journal-title":"BMC Musculoskelet. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e002921","DOI":"10.1136\/bmjoq-2024-002921","article-title":"Clinic of Hope: Bridging infectious disease and orthopaedic surgery in prosthetic joint infection management","volume":"13","author":"Wu","year":"2024","journal-title":"BMJ Open Qual."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tsilika, M., Ntziora, F., and Giannitsioti, E. (2025). Antimicrobial Treatment Options for Multidrug Resistant Gram-Negative Pathogens in Bone and Joint Infections. Pathogens, 14.","DOI":"10.3390\/pathogens14020130"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01385","DOI":"10.1016\/j.idcr.2022.e01385","article-title":"Combination antibiotic therapy for treatment of a patient with infected prosthesis and peri-prosthetic abscess due to Klebsiella pneumoniae harboring New Delhi Metallo (NDM) beta-lactamase","volume":"27","author":"Wong","year":"2022","journal-title":"IDCases"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/cid\/ciad360","article-title":"Periprosthetic Joint Infection: Current Clinical Challenges","volume":"77","author":"Nelson","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"741940","DOI":"10.3389\/fmed.2021.741940","article-title":"Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms","volume":"8","author":"Yao","year":"2021","journal-title":"Front. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40121-023-00773-6","article-title":"Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales","volume":"12","author":"Kaye","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1473-3099(25)00477-3","article-title":"NDM-driven cefiderocol resistance: Effect and therapeutic considerations","volume":"25","author":"Warecki","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"12519","DOI":"10.1039\/D5SC02122G","article-title":"Cefiderocol \u201cunder siege\u201d? Understanding the rise of NDM-mediated resistance to novel agents","volume":"16","author":"Warecki","year":"2025","journal-title":"Chem. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107321","DOI":"10.1016\/j.ijid.2024.107321","article-title":"Emergence of cefiderocol resistance during therapy in NDM-5-producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations","volume":"151","author":"Deroche","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Potter, M.H., Askar, W., Gomez-Abundis, G.F., Carpenter, K., and Kobic, E. (2025). NDM-5 and siderophore receptor mutations drive high-level cefiderocol resistance in Klebsiella pneumoniae: A case series. Infection, 1\u20136.","DOI":"10.1007\/s15010-025-02647-0"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107553","DOI":"10.1016\/j.ijantimicag.2025.107553","article-title":"Susceptibility to new antibiotics and genetic characterisation of carbapenemase-producing Enterobacterales: Low activity of cefiderocol against NDM-producing isolates","volume":"66","author":"Chatzopoulou","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102871","DOI":"10.1016\/j.jiph.2025.102871","article-title":"Addressing antimicrobial resistance: Structural insights into cefiderocol\u2019s mode of action and emerging resistance mechanisms","volume":"18","author":"Salleh","year":"2025","journal-title":"J. Infect. Public Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/cid\/ciab888","article-title":"Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression","volume":"75","author":"Simner","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"14132","DOI":"10.3390\/cimb46120846","article-title":"Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol","volume":"46","author":"Bianco","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e0109024","DOI":"10.1128\/aac.01090-24","article-title":"Detection of cefiderocol and aztreonam\/avibactam resistance in epidemic Escherichia coli ST-361 carrying bla(NDM-5) and bla(KPC-3) from foreign fighters evacuated from Ukraine","volume":"68","author":"Martin","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/phar.4629","article-title":"Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens","volume":"44","author":"Bleick","year":"2024","journal-title":"Pharmacotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.cmi.2024.11.006","article-title":"Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing gram-negative bacteria: A Narrative Review","volume":"31","author":"Sangiorgio","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing Gram-negative pathogens: A Phase 3 randomized trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e00414-18","DOI":"10.1128\/AAC.00414-18","article-title":"Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae","volume":"62","author":"Chew","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam\u2013avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): A descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","first-page":"e28855","article-title":"A Case of New Delhi Metallo-\u03b2-Lactamases (NDM) Citrobacter sedlakii Osteomyelitis Successfully Treated With Ceftazidime-Avibactam and Aztreonam","volume":"14","author":"Rubnitz","year":"2022","journal-title":"Cureus"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"ofad276","DOI":"10.1093\/ofid\/ofad276","article-title":"An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-\u03b2-Lactam Resistance","volume":"10","author":"Simner","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Posteraro, B., De Maio, F., Spanu, T., Vidal Pereira, M.A., Fasano, F.R., and Sanguinetti, M. (2024). Characterization of Metallo \u03b2-Lactamase Producing Enterobacterales Isolates with Susceptibility to the Aztreonam\/Avibactam Combination. Antibiotics, 13.","DOI":"10.3390\/antibiotics13121221"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/jac\/dkaf161","article-title":"Aztreonam\/avibactam activity against Enterobacterales from European medical centres: Summary of 5\u2005years of surveillance prior to approval for clinical use (2019\u20132023)","volume":"80","author":"Sader","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"ofaf250","DOI":"10.1093\/ofid\/ofaf250","article-title":"Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017\u20132022)","volume":"12","author":"Sader","year":"2025","journal-title":"Open Forum Infectious Diseases"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00228-023-03609-x","article-title":"Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation","volume":"80","author":"Das","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"dlad020","DOI":"10.1093\/jacamr\/dlad020","article-title":"In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer","volume":"5","author":"Rolston","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e01699-19","DOI":"10.1128\/AAC.01699-19","article-title":"In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14787210.2024.2351552","article-title":"Eravacycline: A comprehensive review of in vitro activity, clinical efficacy, and real-world applications","volume":"22","author":"Huang","year":"2024","journal-title":"Expert. Rev. Anti-Infect. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"34109","DOI":"10.1038\/s41598-025-19642-y","article-title":"In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii","volume":"15","author":"Abdrabou","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"106178","DOI":"10.1016\/j.ijantimicag.2020.106178","article-title":"In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae","volume":"56","author":"Clark","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ja.2016.73","article-title":"In vitro susceptibility of \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline","volume":"69","author":"Zhang","year":"2016","journal-title":"J. Antibiot."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12866-025-04331-7","article-title":"In vitro activity of Eravacycline against carbapenem-resistant gram-negative bacilli and associated risk factors for non-susceptible infections from a tertiary hospital in fujian, China from 2021 to 2024","volume":"25","author":"Li","year":"2025","journal-title":"BMC Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"dlaf095","DOI":"10.1093\/jacamr\/dlaf095","article-title":"Eravacycline as a last resort for difficult-to-treat resistant Acinetobacter baumannii infections in critically ill patients: Three case reports with pharmacokinetic insights","volume":"7","author":"Mimram","year":"2025","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1496402","DOI":"10.3389\/fmed.2024.1496402","article-title":"Efficacy and safety of eravacycline versus tigecycline for complicated intra-abdominal infections in the ICU: A multicenter, single-blind, parallel randomized controlled trial study protocol","volume":"11","author":"Liu","year":"2024","journal-title":"Front. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s44280-025-00072-4","article-title":"Comparative efficacy of eravacycline and tigecycline in addressing multidrug-resistant Gram-negative bacteria","volume":"3","author":"Zhang","year":"2025","journal-title":"One Health Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jgar.2021.10.020","article-title":"A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals","volume":"29","author":"Hobbs","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early Experience With Eravacycline for Complicated Infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e01174-18","DOI":"10.1128\/AAC.01174-18","article-title":"Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline","volume":"62","author":"Newman","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/11\/1109\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:34:30Z","timestamp":1762331670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/11\/1109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["antibiotics14111109"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14111109","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}